Mizuho Securities, the investment banking arm of Japan's Mizuho Financial Group, has initiated coverage on NeuroPace Inc (NASDAQ: NPCE) with an 'outperform' rating, signalling confidence in the California-based medical technology firm's prospects in the neuromodulation space.
NeuroPace develops and commercialises the RNS System, a brain-responsive neurostimulator designed to reduce seizures in patients with drug-resistant epilepsy. The device monitors brain activity and delivers targeted electrical stimulation to prevent seizures before they begin. Mizuho's analysts reportedly see a strong market opportunity as awareness of the technology grows among neurologists and epilepsy centres.
The initiation comes amid broader interest in neuromodulation therapies, which use implanted devices to alter nerve activity. For UK investors, the coverage highlights a niche but expanding area of medtech, though NeuroPace's shares trade on the Nasdaq and are not directly listed in London. The FTSE 100 edged up 0.3 per cent to 8,215 points on Thursday, with the healthcare sector broadly flat as markets digested mixed corporate earnings.
Analysts at Mizuho are understood to have pointed to NeuroPace's improving reimbursement landscape in the US and its potential for international expansion as key drivers. The RNS System is approved by the US Food and Drug Administration and is used in a growing number of epilepsy treatment centres. However, the company faces competition from larger rivals such as Medtronic and Boston Scientific in the broader neuromodulation market.
For UK pension funds and retail investors with exposure to US healthcare equities through diversified portfolios, the rating serves as a reminder of the high-risk, high-reward nature of specialist medical device stocks. NeuroPace has yet to report full-year profitability, though revenues have been climbing steadily as adoption of its technology increases.